Research on hormone therapy and its effects. Covers menopause symptom relief, bronchiectasis risk, dementia links, and Alzheimer's risk.
A systematic review and meta-analysis found that combining basal insulin with a GLP-1 agonist resulted in improved blood sugar control, similar rates of hypoglycaemia, and greater weight loss compared to other anti-diabetic treatments. This combination therapy showed a 92% greater likelihood of achieving target blood sugar control.
Hot flashes are a prevalent side effect of hormone decline, causing fatigue, sleep disturbance, depression, anxiety, and impaired memory. The study estimates that $339M in healthcare costs and $27M in lost wages can be prevented with effective treatment.
Researchers found that administering EPO immediately after birth significantly reduces brain damage in premature babies. This study builds on previous research showing EPO's neuroprotective effects and holds promise for preventing long-term consequences of preterm birth.
A study published in Scientific Reports found that methadone treatment significantly suppresses testosterone levels in men with opioid addiction, leading to poor quality of life and erectile dysfunction. In contrast, women using methadone for addiction treatment showed no significant change in testosterone levels.
Women seek anti-aging clinicians to treat menopausal symptoms, valuing personalized attention and perceived safety of bioidentical hormones. The study found that these women prioritize relieving symptoms, feeling energized, and avoiding chronic illnesses associated with aging.
Researchers found that bioidentical hormone treatments reduced tumor recurrence and improved cardiovascular and bone health, while also increasing physical activity and cognition. The study's results are promising but require further validation, providing a new direction in the search for alternative hormone therapies.
A recent study found that acupuncture can positively impact both the frequency and severity of hot flashes in women undergoing natural menopause. The analysis revealed that various forms of acupuncture, including traditional Chinese medicine and sham acupuncture, were effective in reducing hot flash frequency for up to three months.
A Baylor University study found that hypnotic relaxation therapy significantly reduced hot flashes in a 69-year-old man with prostate cancer. The treatment also improved his sleep quality, with a 94% decrease in hot flashes and an 87% improvement in sleep quality.
The Practitioner Toolkit for Managing the Menopause is a new resource that helps doctors diagnose and treat menopausal conditions in women globally. The toolkit includes a diagnostic tool, approved hormone therapies, and non-hormonal therapies with evidence-based support.
A new US-based study of over 25,000 older men shows that testosterone therapy is not associated with an increased risk of heart attack. In fact, men with cardiovascular problems who used testosterone had a lower rate of heart attacks compared to those who did not.
Researchers have found that pulsed electromagnetic field therapy significantly reduces the size of the prostate gland in dogs with BPH, a condition affecting millions of men over 50. The treatment is non-invasive, drug-free and painless, offering an alternative to surgery.
The Endocrine Society's publishing imprint Endocrine Press has released a comprehensive guide to treating metabolic emergencies. The book provides clinicians with practical resources for managing acute medical and critically ill patients experiencing endocrine and metabolic crises, such as dangerously low blood sugar or excessive thyro...
A pilot study shows that NM504, a first-in-class GI microbiome modulator, improves glucose tolerance and increases insulin sensitivity in adults with prediabetes. The therapy, which alters microbial populations and their environment in the gastrointestinal tract, also reduces cravings for food.
A new study shows that even triple negative breast cancers with low androgen receptor expression can benefit from anti-androgen receptor therapy. The treatment, which targets the androgen receptor, was found to increase programmed cell death, inhibit growth, and increase necrosis in animal models.
A new study found that testosterone replacement therapy can improve aerobic capacity and lessen its decline with age in older men with limited mobility. The therapy showed a significant reduction in the rate of decline of an important marker of physical fitness in these men.
A new therapy that combines chemotherapy with radiounclide treatment has shown promising results in slowing or stopping the progression of neuroendocrine cancer. In a study of 68 patients, the therapy resulted in stabilization or regression of the disease in 70% of cases, leading to improved patient survival rates.
A study published in JAMA Internal Medicine found that low-dose estrogen therapy and low-dose non-hormonal venlafaxine hydrochloride extended release were both effective in reducing hot flashes and night sweats in menopausal women. The treatment options showed similar efficacy, with a slight superiority of estrogen therapy.
People with Alzheimer's experience a clear improvement in dementia-related behavior after visiting horses under supervision, with reduced fidgeting and resistance to care. The therapy boosts physical activity and lifts their mood, providing a unique way to ease symptoms without drugs.
A clinical study of 158 patients with relapsing remitting multiple sclerosis (RRMS) found that combining Copaxone with estriol improved symptom reduction by 12 months, but the effect waned over time. The results suggest a potential benefit to supplementing Copaxone therapy with estrogen.
The prescription of testosterone in older men is associated with unclear cardiovascular risk. Despite the benefits in younger men, ongoing studies are unlikely to provide reliable safety data due to limited sample sizes and power.
A clinical trial found that six months of hormone therapy added to radiotherapy significantly reduces the risk of prostate cancer relapse and progression. Men who received both treatments had a nearly 50% lower risk of biochemical progression compared to those treated with radiotherapy alone.
The European Menopause and Andropause Society (EMAS) has published a position statement on menopause for medical students, emphasizing the importance of managing postmenopausal health. The statement provides guidance on stages of reproductive aging, menopause terminology, and treatment options, including menopausal hormone therapy and ...
Researchers have identified genetic markers that can predict late recurrence of ER+ breast cancer, allowing for personalized treatment decisions. Women with tumours highly sensitive to oestrogen may benefit from extended hormone therapy beyond five years.
A comprehensive study of over 15,000 men with localized prostate cancer found that primary androgen deprivation therapy does not extend survival. The treatment is associated with serious adverse events and mitigates against its use as a primary treatment option.
A new study found that estradiol hormone therapy prevented degeneration in key brain regions of postmenopausal women at heightened dementia risk. In contrast, Premarin was far less protective. The study suggests that early intervention with estradiol may help stave off dementia.
A recent study found that female hormone therapy, particularly estrogen plus progesterone, significantly improved survival among women with non-small cell lung cancer. The combination of hormone therapy and long-term use showed the most notable improvements in median survival time.
Research finds that moderate-intensity exercise, such as brisk walking or tennis, significantly reduces women's stroke risk. Moderate exercise also helps offset the increased risk seen in postmenopausal women taking menopausal hormones, but not completely.
Researchers at the University of East Anglia have made a significant advance in understanding genetic changes associated with terminal prostate cancer. A genetic mutation has been identified as a key factor in the development of aggressive cancer later in life. This discovery could help identify patients who are at risk of developing f...
Researchers identify androgen and vitamin D receptors as potential targets for breast cancer hormone therapy, offering new treatment options for patients with hormone-dependent breast cancer. The study's findings suggest that triple hormone treatments may be more effective than single hormone treatments.
A new Penn study found that moderate to severe hot flashes continue for nearly five years after menopause and affect over a third of women. The findings challenge current guidelines recommending hormone therapy not exceed 5 years.
A large health care database study has found a twofold increase in the risk of heart attacks among men under 65 using testosterone therapy. The research also confirmed earlier findings that men over 65 experience a similar increased risk.
A study found that adding testosterone to hormone therapy did not significantly improve quality of life, self-esteem, or mood in women with primary ovarian insufficiency. Normalizing testosterone levels may not address underlying factors contributing to mood problems.
A new study found that postmenopausal hormone replacement therapy (HRT) may increase the risk of acute pancreatitis. The risk was higher among women who used systemic therapy and those who had used HRT for more than 10 years.
A new study published in the Journal of Urology reports that prostate cancer patients treated with androgen deprivation therapy (ADT) experienced changes in mental and emotional well-being during treatment, with no significant decline in emotional quality of life two years after treatment. Investigators recommend counseling men about p...
A large population-based study published in Annals of the Rheumatic Diseases found that hormone replacement therapy (HRT) taken regularly after knee or hip replacement reduces the risk of repeat surgery by around 40%. The research also showed that taking HRT for 12 months or more after surgery further decreases the risk, with those rec...
Researchers identified four subtypes of HER2+ breast cancer, including Luminal A, Luminal B, HER2-enriched, and Basal-Like, with varying responses to anti-HER2 therapy and chemotherapy. The study suggests that personalized treatment strategies may improve treatment outcomes for patients.
A new study by the University of British Columbia finds that progesterone poses little or no cardiovascular risk for post-menopausal women experiencing hot flashes and night sweats. The treatment has been shown to be effective in alleviating symptoms without increasing the risk of heart disease.
A study found that testosterone use has increased sharply among older men in the US and UK, with many having normal testosterone levels and non-specific symptoms. The Endocrine Society's guidelines recommend a clinical diagnosis of low testosterone only for men with consistent symptoms and unequivocally low hormone levels.
A new study by LA BioMed finds that daily antibiotic use is the most effective method for preventing recurrent urinary tract infections, reducing recurrence rates to 0.4 per year. Cranberry pills and estrogen therapy also showed benefits, with acupuncture treatments reducing recurrence rates to 0.7 per year.
A phase III clinical trial presented at the 2013 San Antonio Breast Cancer Symposium found that bisphosphonate zoledronate had no effect on event-free survival in women with chemoresistant breast cancer. Researchers also reported that patients with hormone receptor-positive disease were more common, which may impact treatment outcomes.
Research found that women with HER2- and hormone receptor-positive breast cancer treated with neoadjuvant therapy had lower pathologic complete response rates if their tumors had PIK3CA gene mutations. These mutations were more common in HER2-positive breast cancers.
A double-blind, randomized trial found that anastrozole significantly reduced breast cancer incidence among postmenopausal women at high risk for developing the disease. The study showed a 53% reduction in breast cancer incidence with few side effects.
Researchers have found that omitting radiotherapy in older patients with hormone-receptor positive breast cancer who undergo surgery and hormone therapy is a viable option, resulting in a lower rate of unnecessary treatment. The study suggests that these patients are at low risk of recurrence, making radiotherapy optional.
Researchers at A*STAR's Institute of Medical Biology and Institute of Molecular and Cellular Biology have identified a gene encoding a hormone called ELABELA, which is crucial for heart formation in zebrafish embryos. The discovery holds great promise for the development of targeted therapies for heart disease and blood pressure control.
A study found that cognitive behavioral therapy for PTSD reduces symptoms and affects underlying biology, reversing changes in gene expression and brain volume. The therapy was associated with improved symptoms and increased hippocampal volume and FKBP5 gene expression.
A new hormone therapy has been shown to improve the integration of bone grafts used in head and facial reconstruction surgeries. The treatment, which uses parathyroid hormone, enhances bone formation around the grafts and prevents scar tissue from forming, leading to better outcomes for patients.
A new study by MU researchers recommends that women on hormone replacement therapy with progestin avoid ingesting pure apigenin as a supplement. Apigenin, found in celery and other plants, can increase the incidence of breast cancer tumors when combined with synthetic hormones.
A new study found that hormone therapy has no significant impact on the quality of life for recently menopausal women without hot flashes. Women with moderate to severe hot flashes did experience improvements in sleep and other symptoms, but not overall health or sexual well-being.
Researchers at UT Southwestern have found that a cholesterol metabolite called 27-hydroxycholesterol promotes tumor growth in estrogen-receptor positive breast cancers. The discovery may explain why endocrine-based therapies are often unsuccessful, providing a new target for therapy.
A recent study found that men using testosterone therapy have a 29% higher risk of death, heart attack, and stroke compared to those not using the treatment. The study, which analyzed data from over 8,000 patients, highlights the need for caution when prescribing testosterone therapy.
A study found that testosterone therapy was associated with a higher risk of adverse outcomes, including death, heart attack, or ischemic stroke, in men who underwent coronary angiography. The use of testosterone therapy was also linked to an increased risk of these events even among patients without underlying coronary artery disease.
A study found that six patients with estrogen receptor-positive breast cancer developed mutations in the estrogen receptor after taking anti-estrogen therapies, leading to treatment resistance. The discovery sheds light on why patients become resistant to hormonal therapy and offers new insights into developing targeted treatments.
Researchers found that a quick neck injection of local anesthesia can reduce severe hot flashes in women by as much as 50 percent for at least six months. The treatment uses bupivacaine hydrochloride to target the stellate ganglion nerve bundle, providing symptom relief without hormonal therapy.
Scientists have developed a new therapeutic approach for Type 2 diabetes using a novel single molecule hormone that acts on GLP-1 and GIP receptors. The hormone reduces weight and improves blood sugar levels, and may offer unprecedented potential for personalized therapies.
Researchers at Indiana University have developed a molecule combining GLP-1 and GIP peptides, which shows improved therapeutic effects in controlling glucose levels and weight loss. The study demonstrates the potential of this combination as an effective treatment for adult-onset diabetes and obesity.
The Endocrine Society publishes a Clinical Practice Guideline for diagnosing and treating polycystic ovary syndrome (PCOS), a leading cause of infertility in women. The guideline provides clear criteria for diagnosis and treatment recommendations, aiming to address the complexities of this hormone disorder.
An observational study found that testosterone treatment reduced total cholesterol, LDL, triglycerides, and increased HDL in hypogonadal men. Testosterone therapy also lowered systolic and diastolic blood pressure, suggesting a reduction in hypertension.
Scientists at ETH Zurich have created a genetic module that can be controlled via dopamine, which activates the production of an antihypertensive agent. The researchers found that contact with a female mouse triggered feelings of happiness in male mice, correcting hypertension and lowering blood pressure to normal levels.
A comprehensive analysis of hormone therapy trials did not support its use for chronic disease prevention. The study found that menopausal hormone therapy may be suitable for managing symptoms in some women.
A study published in JAMA Internal Medicine compared the cardiovascular safety of conjugated equine estrogens (CEEs) and oral estradiol. The research found a greater risk of venous thrombosis associated with CEEs, but no increased risk of heart attack or ischemic stroke.